-

Frost & Sullivan Institute Honors Organizations Driving Transformative Impact Through Visionary Leadership
SILICON VALLEY, Calif., June 26, 2026 /PRNewswire/ — The Frost & Sullivan Institute is proud to announce the recipients of the 2026 Visionary Growth Leadership Best Practices Recognition, honoring organizations that are setting new benchmarks for business leadership by tackling some of the world’s most critical challenges. This recognition celebrates enterprises that have successfully aligned…
-

Frost & Sullivan Identifies Virtual Healthcare Assistants as a Transformational Force in Healthcare Delivery
New analysis highlights significant growth opportunities in patient- and clinician-facing AI assistants as healthcare organizations seek to improve efficiency, patient engagement, and care outcomes LONDON, June 18, 2026 /PRNewswire/ — Frost & Sullivan’s latest analysis, Innovations and Growth Opportunities in Virtual Healthcare Assistants, finds that artificial intelligence-powered virtual healthcare assistants are poised to transform healthcare delivery…
-

Cloudeva.ai Debuts as a Cloud Decision Intelligence Offering Public Preview Now Open
Bengaluru, Karnataka, India Cloudeva.ai, a cloud intelligence platform that differentiates itself through multi-cloud capabilities & an intelligent advisory bot, officially launches today, with a premise that organizations don’t have a cloud technology problem, they have a cloud decision problem. Amit Gupta, Founder Rapyder and Cloudeva.ai Built by teams with years of hands-on experience supporting cloud…
-

Akums Reports Q2 FY26 Results; Strengthens International Presence
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second quarter of FY26. The CDMO segment remained the key contributor with revenue of Rs. 804 crore. Volumes for the CDMO vertical grew 7% y-o-y, as against muted industry volume growth, reflecting…
-

Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26. Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.







